Introduction : Polycystic ovary syndrome is the major endocrinopathy among reproductive-aged women. The anti-müllerian hormone is a member of the transforming growth factor beta family, it is best known as a serum marker for ovarian function and ovarian reserve and polycystic ovarian syndrome.

The current study aimed to evaluate the potential association of anti-müllerian hormone with obesity in women with polycystic ovarian syndrome and explore the effects of obesity on hormonal changes. Material and methods:A cross-sectional study was conducted in the Gynecology and Obstetrics Department at Salahadeen General Hospital during the period from the 1st of December 2022 to the 30th of June 2023. A convenient sample of 100 women ages 15-45 years who presented with polycystic ovarian syndrome was enrolled in the current study. Results :According to the results of the current study, the levels of the anti-müllerian hormone and inhibin B significantly decreased in obese patients compared to those with overweight and normal weight (P-values were 0.001 for both), while the testosterone level significantly increased in obese patients compared to those with overweight and normal weight (P-value was 0.001). A significant negative correlation was obtained between the anti-müllerian hormone and body mass index. In conclusion, Most patients had higher levels of luteinizing hormone, follicular stimulating hormone, anti-müllerian hormone and testosterone than normal ranges. There were significant associations between the body mass index and the levels of the anti-müllerian hormone, testosterone, and inhibin B. While no significant association was obtained between the patients with obesity, overweight, and normal weight regarding the level of luteinizing hormone and follicular stimulating hormone. There was a significant negative correlation between the body mass index and the anti-müllerian hormone level.

Keyward : polycystic ovary ' antimulerien hormone ' obese patient